STUDY OBJECTIVES: To evaluate the usefulness of procalcitonin serum levels as a predictor of etiology and prognosis in adult patients with community-acquired pneumonia (CAP) when they are stratified according to severity. DESIGN: One-year, population-based, prospective study. SETTING: University teaching hospital. PATIENTS: All adult patients who received a diagnosis of CAP throughout the study period. INTERVENTIONS AND MEASUREMENTS: An extensive noninvasive microbiological workup was performed. In patients who gave informed consent, a blood sample was collected at the time the diagnosis of CAP was established to measure biological markers. Procalcitonin levels were measured by a commercially available monoclonal immunoluminometric assay (limit of detection, 0.1 microg/L). Patients were classified according to microbial diagnosis, Patients Outcome Research Team pneumonia severity index (PSI), and outcome measures, and procalcitonin levels were compared among groups. RESULTS: Of 240 patients who received a diagnosis of CAP during the study period, procalcitonin concentrations were measured in 185 patients (77.1%). Levels were higher in patients with high-severity risk classes (PSI classes III-V) [p = 0.01] and in those with complications (p = 0.03) or death (p < 0.0001). Among patients classified into PSI low-severity risk classes (classes I-II), levels tended to be higher in those with bacterial etiology (p = 0.08); in this group, a serum procalcitonin level > or = 0.15 microg/L was more frequently found in patients with bacterial pneumonia than in those with nonbacterial pneumonia (p = 0.03). In patients with higher-severity risk classes, no significant differences were observed in procalcitonin levels among etiologic groups, but higher concentrations were associated with development of complications (p = 0.01) and death (p < 0.0001). CONCLUSIONS: Procalcitonin contribution to the evaluation of CAP varies according to severity. While procalcitonin may have a role to predict the microbial etiology in patients with a low PSI score, in patients classified within high PSI risk classes, it is a prognostic marker rather than a predictor of etiology.
STUDY OBJECTIVES: To evaluate the usefulness of procalcitonin serum levels as a predictor of etiology and prognosis in adult patients with community-acquired pneumonia (CAP) when they are stratified according to severity. DESIGN: One-year, population-based, prospective study. SETTING: University teaching hospital. PATIENTS: All adult patients who received a diagnosis of CAP throughout the study period. INTERVENTIONS AND MEASUREMENTS: An extensive noninvasive microbiological workup was performed. In patients who gave informed consent, a blood sample was collected at the time the diagnosis of CAP was established to measure biological markers. Procalcitonin levels were measured by a commercially available monoclonal immunoluminometric assay (limit of detection, 0.1 microg/L). Patients were classified according to microbial diagnosis, Patients Outcome Research Team pneumonia severity index (PSI), and outcome measures, and procalcitonin levels were compared among groups. RESULTS: Of 240 patients who received a diagnosis of CAP during the study period, procalcitonin concentrations were measured in 185 patients (77.1%). Levels were higher in patients with high-severity risk classes (PSI classes III-V) [p = 0.01] and in those with complications (p = 0.03) or death (p < 0.0001). Among patients classified into PSI low-severity risk classes (classes I-II), levels tended to be higher in those with bacterial etiology (p = 0.08); in this group, a serum procalcitonin level > or = 0.15 microg/L was more frequently found in patients with bacterial pneumonia than in those with nonbacterial pneumonia (p = 0.03). In patients with higher-severity risk classes, no significant differences were observed in procalcitonin levels among etiologic groups, but higher concentrations were associated with development of complications (p = 0.01) and death (p < 0.0001). CONCLUSIONS: Procalcitonin contribution to the evaluation of CAP varies according to severity. While procalcitonin may have a role to predict the microbial etiology in patients with a low PSI score, in patients classified within high PSI risk classes, it is a prognostic marker rather than a predictor of etiology.
Authors: Wesley H Self; Carlos G Grijalva; Derek J Williams; Alison Woodworth; Robert A Balk; Sherene Fakhran; Yuwei Zhu; D Mark Courtney; James Chappell; Evan J Anderson; Chao Qi; Grant W Waterer; Christopher Trabue; Anna M Bramley; Seema Jain; Kathryn M Edwards; Richard G Wunderink Journal: Chest Date: 2016-04-21 Impact factor: 9.410
Authors: Todd A Florin; Lilliam Ambroggio; Cole Brokamp; Yin Zhang; Mantosh Rattan; Eric Crotty; Michael A Belsky; Sara Krueger; Thomas N Epperson; Andrea Kachelmeyer; Richard Ruddy; Samir S Shah Journal: Pediatrics Date: 2020-05-13 Impact factor: 7.124
Authors: Sofya Tokman; Christopher F Barnett; Leah G Jarlsberg; Pam R Taub; Saskia den Boon; J Lucian Davis; Adithya Cattamanchi; William Worodria; Alan Maisel; Laurence Huang Journal: Respirology Date: 2014-01-26 Impact factor: 6.424
Authors: David T Huang; Lisa A Weissfeld; John A Kellum; Donald M Yealy; Lan Kong; Michael Martino; Derek C Angus Journal: Ann Emerg Med Date: 2008-03-17 Impact factor: 5.721
Authors: Stefan Krüger; Santiago Ewig; Jana Papassotiriou; Jan Kunde; Reinhard Marre; Heike von Baum; Norbert Suttor; Tobias Welte Journal: Respir Res Date: 2009-07-12
Authors: Cédric Daubin; Jean-Jacques Parienti; Sabine Fradin; Astrid Vabret; Michel Ramakers; Nicolas Terzi; François Freymuth; Pierre Charbonneau; Damien du Cheyron Journal: BMC Infect Dis Date: 2009-09-21 Impact factor: 3.090